>
COMMANDS Global: GP Symbol: IBM FA
↑↓ Navigate Enter Open Esc Close ` Toggle

Summary

3.64 -0.03 (-0.82%) 09/16/2026
Bicycle Therapeutics plc (BCYC)
Performance
Historical returns
1D
-0.82%
1W
-4.96%
1M
-9.00%
3M
-9.45%
6M
-27.92%
1Y
-47.63%
5Y
-91.77%
Snapshot
Key statistics
Close
3.64
Change
-0.03
Change %
-0.82%
Open
3.68
Day Range
3.61 – 3.73
Volume
599,854
Avg Vol (20d)
392,594
Rel Vol
1.53x
52W Range
3.61 - 9.16
vs 52W High
-60.26%
vs 52W Low
0.83%
Gap
-0.21
Market Cap
USD 252.60M
Beta
1.47
Price Chart
Advanced chartCompare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Bull vs Bear
4 bullish · 8 bearish points
Bullish view
  • Gross margin improved to 100.0% from -2,332.5% a year ago.
  • FY2025 earnings rose 29.5% to -$218.96M.
  • Sits 202.2% below the average analyst target of $11.00 across 5 firms.
  • 3 of 5 covering analysts rate the shares a buy.
Bearish view
  • Operating margin compressed to -8,673.9% in the Jun 2026 quarter from -2,965.8% a year earlier.
  • Revenue fell 78.5% year on year in the Jun 2026 quarter.
  • Missed consensus EPS in 4 of the last 8 quarters.
  • The Jul 2026 quarter missed on EPS by $0.16 (27.6% below consensus).
  • Revenue in the same quarter came in $3.59M short of consensus.
  • Trades 28.5% below its 200-day average, a downtrend still intact.
  • Still 59.0% below its 52-week high of $8.87.
  • Lagged the S&P 500 by 10.2% over the last quarter (-9.5% against +0.8%).
Both sides are generated from reported financials, consensus estimates, analyst targets and the price series — not from opinion.
Notable Price Movement
Historical returns
Sep 16
2026
$3.64 0.82%Latest52W Low
Bicycle Therapeutics fell 0.82% to $3.64, on 1.6× average volume. Shares set a 52-week closing low. The move left the stock 59.0% below its 52-week high.
Sep 15
2026
$3.67 5.66%52W Low
Bicycle Therapeutics fell 5.66% to $3.67, its biggest one-day drop in 2 months and a 2.4σ move against its 60-day volatility, on 1.5× average volume. This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.05% that session, leaving about 5.0 points of the move unexplained by the market after adjusting for a 1.47 beta. Shares closed near the session low (8% of the day's range) and set a 52-week closing low. Historically, after 2.4σ-or-larger down days, Bicycle Therapeutics returned -2.38% on average over the following 5 sessions (36% positive, n=11).
Sep 10
2026
$3.83 4.37%52W Low
Bicycle Therapeutics fell 4.37% to $3.83, its biggest one-day drop in 2 months and a 1.8σ move against its 60-day volatility, on 6.5× average volume. This was largely stock-specific: the S&P 500 fell 0.60% while Healthcare peers (XLV) fell 0.55% that session, leaving about 3.5 points of the move unexplained by the market after adjusting for a 1.47 beta. Shares opened with a 1.00% gap down, closed near the session low (9% of the day's range), set a 52-week closing low and marked a 3rd consecutive decline.
Sep 9
2026
$4.01 4.19%
Bicycle Therapeutics fell 4.19% to $4.01, its biggest one-day drop in 2 months and a 1.8σ move against its 60-day volatility, on 1.4× average volume. This was largely stock-specific: the S&P 500 fell 0.46% while Healthcare peers (XLV) fell 0.33% that session, leaving about 3.5 points of the move unexplained by the market after adjusting for a 1.47 beta. Shares opened with a 1.44% gap down, closed near the session low (12% of the day's range) and lost their 50-day moving average.
Sep 2
2026
$4.30 4.88%
Bicycle Therapeutics rose 4.88% to $4.30, its biggest one-day gain in 4 weeks and a 2.1σ move against its 60-day volatility. This was largely stock-specific: the S&P 500 gained 0.44% while Healthcare peers (XLV) rose 0.75% that session, leaving about 4.1 points of the move unexplained by its sector. Shares reclaimed their 20- and 50-day moving averages.
Aug 17
2026
$4.00 2.56%Earnings
Bicycle Therapeutics rose 2.56% to $4.00. This was largely stock-specific: the S&P 500 fell 0.47% while Healthcare peers (XLV) fell 0.19% that session, leaving about 2.8 points of the move unexplained by its sector. Shares opened with a 1.92% gap up and closed near the session high (83% of the day's range). It came 1 session after the Q2 2026 print.
Computed from adjusted closes over the last 22 sessions; attribution vs SPY and XLV.
Price Performance
All periods
PeriodPeriod LowPeriod HighPerformance
1-Month3.61 +0.83%
on 09/16/26
Open 4.00
4.51 -19.29%
on 08/21/26
-0.36 (-9.00%)
since 08/17/26
3-Month3.61 +0.83%
on 09/16/26
Open 4.02
4.52 -19.38%
on 07/07/26
-0.38 (-9.45%)
since 06/16/26
6-Month3.61 +0.83%
on 09/16/26
Open 5.07
5.41 -32.72%
on 04/17/26
-1.43 (-28.21%)
since 03/17/26
YTD3.61 +0.83%
on 09/16/26
Open 6.68
7.34 -50.41%
on 01/22/26
-3.04 (-45.51%)
since 01/02/26
52-Week3.61 +0.83%
on 09/16/26
Open 6.86
9.16 -60.26%
on 10/09/25
-3.22 (-46.94%)
since 09/15/25
5-Year3.61 +0.83%
on 09/16/26
Open 40.55
62.07 -94.14%
on 11/15/21
-36.91 (-91.02%)
since 09/08/21
New Highs
Historical highs
5-Day
2×
-6.43% from peak
1-Month
4×
-17.08% from peak
3-Month
6×
-17.46% from peak
6-Month
5×
-31.71% from peak
YTD
3×
-49.58% from peak
52-Week
7×
-58.96% from peak
2-Year
1×
-86.77% from peak
3-Year
14×
-86.77% from peak
5-Year
11×
-94.05% from peak
10-Year
n/a
not enough history
Financial SnapshotFY 2025
Full financials
Revenue
USD 72.59M
+105.8% YoY
Net Income
-USD 218.96M
+29.5% YoY
EPS
-3.16
+8.6% YoY
Gross Margin
100.0%
Operating Margin
-341.3%
Net Margin
-301.7%
EBITDA
-USD 212.18M
Free Cash Flow
-USD 252.61M
-348.0% margin
ROE
-35.9%
ROA
-30.5%
Debt / Equity
0.03x
net debt -USD 610.59M
Cash & Equiv.
USD 628.11M
News
All news
08/03 12:04 ET · pymnts.com
Visa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatch
Visa is set to acquire Israel-based fraud intelligence company BioCatch for $2.4 billion. The all-cash deal, announced Monday (Aug. 3) aims to complement Visa's cyber, fraud, risk and security solutions and help clients protect themselves and customers from a growing range of fraud-related threats.
07/30 07:00 ET · businesswire.com
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended...
05/21 17:00 ET · businesswire.com
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of initial data from the...
04/30 07:00 ET · businesswire.com
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended...
04/21 10:31 ET · businesswire.com
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster...
04/20 07:00 ET · businesswire.com
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from its EphA2 pipeline at the American...
04/16 10:55 ET · zacks.com
Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
04/07 04:59 ET · defenseworld.net
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) CEO Kevin Lee sold 5,967 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total value of $29,297.97. Following the completion of the sale, the...

Market News ×
Loading news…